Kipp Weiskopf

Head of Antibody Therapeutics and Biologics at Beth Israel Deaconess Medical Center

Speaker

Kipp Weiskopf, M.D., PhD, is Head of Antibody Therapeutics and Biologics at Beth Israel Deaconess Medical Center’s Cancer Research Institute. He leads an independent research laboratory that studies macrophages and other innate immune cells in the tumor microenvironment. The lab also pursues a multipronged immunoengineering effort to create novel antibodies, bispecific agents, and ADCs to benefit patients with cancer and other life-threatening diseases. Dr. Weiskopf previously earned his medical and graduate degrees at Stanford University. As a member of Dr. Irving Weissman’s laboratory, he helped define the CD47/SIRPa interaction as an immune checkpoint that regulates macrophage phagocytosis. He began his laboratory as a Valhalla Fellow at Whitehead Institute for Biomedical Research.. Dr. Weiskopf is an inventor on over 20 issued U.S. patents pertaining to macrophage-directed therapies. He co-founded ALX Oncology, a biotech company that is investigating macrophage-directed therapies in multiple clinical trials for cancer. Other technology that Dr. Weiskopf invented has been licensed to Forty Seven, Inc. (acquired by Gilead). More recently, he co-founded DEM Biopharma and Solu Therapeutics to create novel therapies for cancer and other life-threatening diseases. Dr. Weiskopf is concurrently appointed as a physician at Dana-Farber Cancer Institute in the Department of Medical Oncology. He previously completed his medical training in Internal Medicine at Brigham and Women’s Hospital and is board certified in Internal Medicine. He has been recognized with a number of awards including a Winston Churchill Scholarship, the Harold M. Weintraub Graduate Student Award, first place in the Collegiate Inventors Competition, an ASCO Young Investigator Award, and the AACR-AstraZeneca Career Development Award for Physician-Scientists, in Honor of José Baselga, a Department of Defense Peer Reviewed Cancer Research Program Career Development Award, and a National Cancer Institute R01 research project grant. Dr. Weiskopf previously earned a B.A. from Amherst College and an M.Phil. in genetics from University of Cambridge.